Cameron Reilly

Managing Director

Corridor Capital

Joined: 2011

Office Phone:

(310) 442-7000


  Pro - Try 1 Week Free
 

    and access,

  •     75K PE/M&A Contacts
  •     +
  •     4.5K PE Firms
  •     3.6K M&A Advisors
  •     193K Transactions
  •     197K Companies

  •     Market Services
  •     Build Lists
  •     Research Sectors
  •     Uncover Opportunities

Bio

Cameron Reilly joined Corridor Capital in 2011 and brings a decade of principal investment experience, as well as, a strong background in corporate finance, M&A advisory and operations. Prior to joining Corridor, Cameron was as a Principal with Black Canyon Capital, a Los Angeles based private capital investment firm, where he helped build the firm’s middle market control equity investment strategy and was responsible for sourcing, executing and managing investments in the niche manufacturing, business services, health care, and consumer/retail spaces. Cameron has also held investment professional roles with the Yucaipa Companies and Sentinel Capital Partners and gained operating experience while serving in a business development and finance capacity for Vantage Oncology (a leading private equity backed health care professional services firm). He began his career as an analyst with Salomon Smith Barney (now Citigroup), executing an extensive range merger and acquisition and corporate finance transactions in New York and London. Cameron currently serves on the boards of Wetmore Tool & Engineering, Inc., US Industrial Tool & Supply, Inc., Arvan, Inc.. He holds an M.B.A. with Honors from the Anderson School of Business at UCLA and graduated with a B.S. in Economics, magna cum laude, from the Wharton School of Business at the University of Pennsylvania, where he was a member of the Wrestling and Sprint Football teams.

Education

UCLA Anderson School of Management , California,
1 of 45

The Wharton School of the University of Pennsylvania , Pennsylvania,
1 of 523

Work History

Black Canyon Capital

The Yucaipa Companies

Sentinel Capital Partners

Vantage Oncology, Inc.